Iparomlimab and Tuvonralimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy for CC

Currently, the survival rate of locally advanced cervical cancer is low, posing a significant challenge in the treatment of cervical cancer. Radical chemoradiotherapy is considered the standard treatment for patients with locally advanced cervical cancer. However, 23.3% to 34.4% of patients still experience recurrence or subsequent metastasis. Radical surgery following neoadjuvant chemotherapy is an alternative to concurrent chemoradiotherapy, but it also has limitations: for approximately 9.8% to 30.6% of patients who do not respond to neoadjuvant chemotherapy, effective local treatment may b

Trial Details

NCT ID
NCT06878222
Phase
PHASE2
Sponsor
Obstetrics & Gynecology Hospital of Fudan University
Status
RECRUITING
Cancer Type
Adenocarcinoma Cervical Cancer
Interventions
  • Neoadjuvant Chemotherapy
  • Immunotherapy
  • Radical surgery
  • Fertility-preserving surgery
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Histologically confirmed cervical squamous cell carcinoma, cervical adenocarcinoma, or cervical adenosquamous carcinoma.
  • -Arm 1 (Locally Advanced cervical cancer): Patients with locally advanced cervical cancer classified as FIGO 2018 stages IB3, IIA2, IIB, or IIICr (…
  • Arm2 (cervical cancer patients desiring fertility-sparing treatment): Patients with cervical cancer classified as FIGO 2018 stages IB2, IB3 (lesion…
  • 3)Planned to undergo surgical treatments of cervical cancer.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Cervical Cancer Trials on Trialify →